Notícias

The prescription data collected for Eli Lilly's new weight-loss pill, Foundayo, is flawed, analysts said Friday.

Veeva Systems stock pops following S&P 500 inclusion announcement.

Eli Lilly (LLY) reported strong Q1 results driven by GLP-1 drugs, with fundamentals remaining solid

Eli Lilly's (LLY) international rollout of its new oral weight-loss drug is off to a strong start, w

Assessing Eli Lilly after a strong multi year run Eli Lilly (LLY) is back in focus for many investors after a long stretch of strong multi year total returns and significant scale, with a market value around US$761.7b and annual revenue of US$65.2b. See our latest analysis for Eli Lilly. The latest 9.8% 1 day share price return takes Eli Lilly to US$934.60, while the 1 year total shareholder return of 18.56% and 5 year total shareholder return above 4x suggest long term momentum has remained...

Novo will sell 1.5 mg, 4 mg and 9 mg Ozempic pills as it rebrands Rybelsus in the US.

Beneath Eli Lilly's (LLY) headline numbers lies a structural business model shift that the broader market seems to currently undervalue, driven in part by a recent valuation penalty following Novo Nordisk's faster initial prescription ramp for its oral therapy. While early volume data favors the competitor’s established brand capture, the central equity debate remains focused on the friction between high demand and pricing pressure from pharmacy benefit managers. Critics highlight dropping reali